SAB Biotherapeutics

SAB Biotherapeutics is a clinical-stage biopharmaceutical company with a proprietary technology to produce fully human polyclonal antibodies without the need for human plasma donors.

SAB Biotherapeutics uses its novel immunotherapy platform to produce life-saving therapies.

SAB Biotherapeutics was founded in 2014 by Eddie J. Sullivan, Eddie Hamilton and Christine Hamilton. The company is headquartered in Sioux Falls, South Dakota.

 

SAB Biotherapeutics has developed a first-of-its-kind therapeutic engine—unleashing the power of the body’s native biological defense system to produce immunotherapies that truly match and overpower the complexity, diversity, and evolution of human disease.

 

SAB Biotherapeutics by utilizing some of the most complex genetic engineering and antibody science has developed the DiversitAb™ platform to harness the native human antibody immune response. Its novel therapeutic engine can produce medicines—human polyclonal antibodies—for a broad array of pathogens to treat modern health challenges such as seasonal influenza, Type 1 diabetes, and cancers.

 

SAB Biotherapeutics is backed by South Dakota Equity Partners, Merck, National Institutes of Health and others. The company closed its Series B with $14M on Jul 17, 2020. This brings SAB's total funding to $40.4M to date.

 

 

  • Year founded: 2014
  • Funding Info: $40.4M over 4 Rounds (Latest Funding Type: Series B)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: Sioux Falls
  • State: South Dakota
  • Country: United States
Related businesses